Ultragenyx (RARE) Reports Q4 Earnings: What Key Metrics Have to Say

Core Insights - Ultragenyx reported $207 million in revenue for Q4 2025, marking a year-over-year increase of 25.6% [1] - The company's EPS for the same period was -$1.29, an improvement from -$1.39 a year ago, but below the consensus estimate of -$1.20 [1] - The revenue exceeded the Zacks Consensus Estimate of $202.92 million by 2.01%, while the EPS fell short by 7.32% [1] Revenue Breakdown - Dojolvi generated $32 million in revenue, surpassing the average estimate of $30.28 million, with a year-over-year increase of 2.9% [4] - Evkeeza achieved $17 million in revenue, exceeding the estimated $16.37 million, reflecting a significant year-over-year growth of 63.9% [4] - Mepsevii reported $13 million in revenue, above the average estimate of $10.81 million, also showing a year-over-year increase of 63% [4] - Total Crysvita revenue reached $145 million, exceeding the average estimate of $135.25 million [4] - Overall product sales were $102 million, which was below the estimated $114.76 million, but still represented a year-over-year increase of 41.9% [4] - Royalty revenue amounted to $105 million, surpassing the average estimate of $91.57 million, with a year-over-year change of 12.9% [4] Stock Performance - Over the past month, Ultragenyx shares have returned -0.8%, compared to a -0.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]